NASDAQ: IMVT

Immunovant, Inc.

Healthcare | Biotechnology

No licensed closing price on file for IMVT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Immunovant, Inc. (NASDAQ: IMVT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:13 UTC.

What Immunovant, Inc. does

Immunovant is a clinical-stage immunology company developing IMVT-1402, an inhibitor of the neonatal fragment crystallizable receptor (FcRn), to treat autoimmune diseases caused by high levels of pathogenic immunoglobulin G (IgG) antibodies. The company is conducting studies in six indications—Graves disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren's disease, and cutaneous lupus erythematosus—with potentially registrational trials planned in the first five.

Summarized from Immunovant, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for IMVT are available in Oxford Ledge.
Open IMVT in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-09

2026-10-09Chief Technology OfficerSale-2,213$70.9K
2026-10-09Chief Operating OfficerSale-2,241$71.8K
2026-10-09Chief Legal OfficerSale-1,327$42.5K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC16,186,469$623.66M-4.3%
Deep Track Capital, LP9,341,151$359.91M-19.0%
BlackRock, Inc.7,180,897$276.68M+9.2%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-11-21Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-07-29Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-04-21Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Immunovant Q1 2027 Earnings Call: Complete Transcript
Benzinga2026-10-14
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
prnewswire.com2026-10-12
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
businesswire.com2026-10-11NEG
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Yahoo2026-10-08
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next
Yahoo2026-09-30NEG

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IMVT and 5,000+ tickers.

Create a free account — keep IMVT

For your agent

GET /api/data?ticker=IMVT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt